Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World Orphan Drug Congress USA, on April 21.

Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World  Orphan Drug Congress USA, Friday, at 12:20 PM on April 21. Wardmar Park Marriott Washington, DC Roundtable 4: Partnerships- successful collaboration between a rare disease foundation and a pharmaceutical company to advance preclinical and clinical research in Rett…

Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor

  NEW YORK, NY – April 3, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announced today the presentation of new…